Cargando…

The value of 18F-FDG PET/CT in patient with neurofibromatosis type 1: A case report and literature review

RATIONALE: Neurofibromatosis type one (NF1) is characterized by cutaneous and nervous lesions, and the tendency to form plexiform neurofibromas (PNFs). PNFs may undergo malignant transformation into a malignant peripheral nerve sheath tumors (MPNSTs). MPNSTs often carry an significant morbidity and...

Descripción completa

Detalles Bibliográficos
Autores principales: Ren, Jiazhong, Yang, Guoren, Zhou, Jing, Fu, Zheng
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Wolters Kluwer Health 2018
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5976335/
https://www.ncbi.nlm.nih.gov/pubmed/29768331
http://dx.doi.org/10.1097/MD.0000000000010648
Descripción
Sumario:RATIONALE: Neurofibromatosis type one (NF1) is characterized by cutaneous and nervous lesions, and the tendency to form plexiform neurofibromas (PNFs). PNFs may undergo malignant transformation into a malignant peripheral nerve sheath tumors (MPNSTs). MPNSTs often carry an significant morbidity and mortality. PATIENT CONCERNS: A 17-year-old man with gradually increased multiple subcutaneous soft lesions. He also presented with numerous lentigines and multiple café-au-lait macules on his body. DIAGNOSES: These were collagen neurofibroma, which were definitively diagnosed by pathology. NF1 was eventually diagnosed. INTERVENTIONS: These lesions were abnormal uptake of radiotracer, when he underwent positron emission tomography (PET) with fluorine-18-fluorodeoxyglucose (FDG) scanning. Standard uptake value (SUV) and other parameters can help to distinguish benign and malignant lesions in patient with NF1. He was underwent serials (18)F-FDG PET/CT examinations to followed up, in order to monitor these lesions malignant transformation. OUTCOMES: So far, these subcutaneous soft lesions were not malignant transformation. LESSONS: (18)F-FDG PET/CT is being increasingly used as an imaging modality to discover the systemic lesions and to discriminate between benign and malignant plexiform neurofibromas.